Boston Scientific (BSX) Announces FDA Approval of New Heart Failure Lead
More News related to BSX
- Trading Radar 7/21: Apple (AAPL), Bank of America (BAC), Merck (MRK), American Express (AXP) Report; Leading Indicators for June Due
- Boston Scientific (BSX) volatility Flat at 46 into EPS & Outlook
- Boston Scientific (BSX) Receives FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
- Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
- Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results
Boston Scientific Corporation (NYSE: BSX) announced FDA approval of its ACUITY(R) Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators (CRT-D) and cardiac resynchronization therapy pacemakers (CRT-P), both of which treat heart failure. The ACUITY Spiral lead is the Company's fifth generation left ventricular lead and second in the ACUITY family of left ventricular leads. The product features a spiral fixation design and small lead tip profile (4.1 French tapering to 2.6 French) for placement of the lead in veins of varying sizes, including difficult-to-access veins. A lead is an insulated wire that carries the heart signal to the implanted device and delivers energy from the device to the heart. In most cases, leads are passed into the heart through veins.
Related Categories
FDAStocks Mentioned
+0.23Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
